Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 801 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 24 juin 2026 et désignation d’un mandataire ad hoc
Regulatory Filings
2026-06-03 French
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
Regulatory Filings
2026-06-03 English
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
Annual Report Classification · 95% confidence The document is a detailed financial announcement titled "Nicox annonce ses résultats financiers 2025 et fait un point sur son activité" which translates to "Nicox announces its 2025 financial results and provides an update on its activity." It includes comprehensive financial data such as income statement, balance sheet, and detailed commentary on revenues, losses, and strategic outlook. The document references the fiscal year 2025 and contains actual financial statements and analysis. It is not a brief announcement or a notice of report publication but a full financial report for the year. Therefore, it fits the definition of an Annual Report (10-K equivalent). FY 2025
2026-04-30 French
Nicox Provides Full Year 2025 Financial Results and Corporate Update
Annual Report Classification · 95% confidence The document is a press release dated April 30, 2026, providing full year 2025 financial results and a corporate update for Nicox SA. It includes detailed financial data such as revenue, net loss, operating expenses, income statement, and balance sheet figures for the full fiscal year 2025. The document also discusses future milestones, regulatory updates, and strategic plans. The presence of comprehensive financial statements and analysis for the full fiscal year indicates this is a full annual financial report rather than a brief earnings release or announcement. The document length (11,641 characters) and detailed financial tables confirm it is not a short announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K) type filing, as it covers the company's full year financial performance and activities. FY 2025
2026-04-30 English
Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026
Share Issue/Capital Change Classification · 85% confidence The document is a press release reminding warrant holders (BSA) of the final exercise date and outlining the terms (ISIN, exercise period, parity, price) and potential share issuance (4,009,038 new shares). It is not a full financial report or earnings release but an announcement about a capital change (exercise of warrants leading to share issuance). This matches our category for share issue/capital change announcements (SHA).
2026-04-20 French
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
Capital/Financing Update Classification · 85% confidence The document is a press release reminding warrant holders of the expiration and exercise terms of the company’s June 2024 equity warrants. It deals with the company’s capital structure and financing instrument (warrants), rather than financial results, management changes, or dividend information. Therefore it is best classified as a Capital/Financing Update (CAP).
2026-04-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.